Skip to content
High Tech Series A Founded 2014

ViAqua

ViAqua develops RNA-i formulated drug delivery technology for aquaculture, offering orally administered treatments that prevent viral epidemics in aquaculture. Its proprietary RNAi nanoparticle formulation is delivered via feed or immersion, triggering cell reactions to disable viral infections. Founded in 2014 in Rehovot, Israel, the company has raised $12.6M in Series A funding from investors including Rabo…

📍 Rehovot, Israel · Nanotechnology,

Funding snapshot

Last roundSeries A
Amount$8M
Date5 September 2023
Total raised$13M
Team size14

About

ViAqua develops RNA-i formulated drug delivery technology for aquaculture, offering orally administered treatments that prevent viral epidemics in aquaculture. Its proprietary RNAi nanoparticle formulation is delivered via feed or immersion, triggering cell reactions to disable viral infections. Founded in 2014 in Rehovot, Israel, the company has raised $12.6M in Series A funding from investors including Rabo Ventures, Nutreco, and S2G Investments. Developer of RNA-i formulated drug delivery technology for aquaculture. The company has developed orally administered treatment in aquaculture to stop diseases from developing and to prevent viral epidemics. Its drug delivery platform uses proprietary RNAi nanoparticle formulation which is delivered via feed or immersion to produce and triggers a cell reaction to disable the viral infection.

Business model

Nanotechnology > Nanoenabled Products > Life Science > Drug Delivery > Encapsulation,

Aquaculture Tech > Health Management > Disease Management > Oral Vaccines

Team background

College Wise > Tel Aviv University

Institutional investors

Rabo Ventures The Trendlines Group Nutreco S2G Investments Thai Union Group Agriline Technion - Israel Institute of Technology Israel Innovation Authority Clay Capital

Latest coverage

No articles yet.

Raising like ViAqua?

Analyze your pitch deck before your next raise.

Analyze My Deck →